Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Overview and Summary 2024
- Author:
Young Joo PARK
1
;
Eun Kyung LEE
;
Young Shin SONG
;
Bon Seok KOO
;
Hyungju KWON
;
Keunyoung KIM
;
Mijin KIM
;
Bo Hyun KIM
;
Won Gu KIM
;
Won Bae KIM
;
Won Woong KIM
;
Jung-Han KIM
;
Hee Kyung KIM
;
Hee Young NA
;
Shin Je MOON
;
Jung-Eun MOON
;
Sohyun PARK
;
Jun-Ook PARK
;
Ji-In BANG
;
Kyorim BACK
;
Youngduk SEO
;
Dong Yeob SHIN
;
Su-Jin SHIN
;
Hwa Young AHN
;
So Won OH
;
Seung Hoon WOO
;
Ho-Ryun WON
;
Chang Hwan RYU
;
Jee Hee YOON
;
Ka Hee YI
;
Min Kyoung LEE
;
Sang-Woo LEE
;
Seung Eun LEE
;
Sihoon LEE
;
Young Ah LEE
;
Joon-Hyop LEE
;
Ji Ye LEE
;
Jieun LEE
;
Cho Rok LEE
;
Dong-Jun LIM
;
Jae-Yol LIM
;
Yun Kyung JEON
;
Kyong Yeun JUNG
;
Ari CHONG
;
Yun Jae CHUNG
;
Chan Kwon JUNG
;
Kwanhoon JO
;
Yoon Young CHO
;
A Ram HONG
;
Chae Moon HONG
;
Ho-Cheol KANG
;
Sun Wook KIM
;
Woong Youn CHUNG
;
Do Joon PARK
;
Dong Gyu NA
;
Author Information
- Publication Type:REVIEW ARTICLES
- From:International Journal of Thyroidology 2024;17(1):1-20
- CountryRepublic of Korea
- Language:EN
- Abstract: Differentiated thyroid cancer demonstrates a wide range of clinical presentations, from very indolent cases to those with an aggressive prognosis. Therefore, diagnosing and treating each cancer appropriately based on its risk status is important. The Korean Thyroid Association (KTA) has provided and amended the clinical guidelines for thyroid cancer management since 2007. The main changes in this revised 2024 guideline include 1) individualization of surgical extent according to pathological tests and clinical findings, 2) application of active surveillance in low-risk papillary thyroid microcarcinoma, 3) indications for minimally invasive surgery, 4) adoption of World Health Organization pathological diagnostic criteria and definition of terminology in Korean, 5) update on literature evidence of recurrence risk for initial risk stratification, 6) addition of the role of molecular testing, 7) addition of definition of initial risk stratification and targeting thyroid stimulating hormone (TSH) concentrations according to ongoing risk stratification (ORS), 8) addition of treatment of perioperative hypoparathyroidism, 9) update on systemic chemotherapy, and 10) addition of treatment for pediatric patients with thyroid cancer.
